The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Allogeneic Peripheral Blood Stem-Cell Compared With Bone Marrow Transplantation in the Management of Hematologic Malignancies: An Individual Patient Data Meta-Analysis of Nine Randomized Trials
Open accessAbstract
Purpose: Considerable uncertainty exists regarding relative effects of allogeneic peripheral blood stem cells transplantation (PBSCT) versus bone marrow transplantation (BMT) on outcomes of patients with hematologic malignancies. Patients and Methods: To provide the totality of research evidence related to the effects of PBSCT versus BMT, we conducted an individual-patient data meta-analysis using data from nine randomized trials enrolling 1,111 adult patients. Results: Compared with BMT, PBSCT led to faster neutrophil (odds ratio [OR] = 0.31; 95% CI, 0.25 to 0.38; P < .00001) and platelet engraftment (OR = 0.52; 95% CI, 0.44 to 0.61; P < .00001). PBSCT was associated with a significant increase in the development of grade 3-4 acute graft-versus-host disease (GVHD; OR = 1.39; 95% CI, 1.03 to 1.88) and extensive (47% v 31% at 3 years; OR = 1.89; 95% CI, 1.47 to 2.42; P < .000001) and overall chronic GVHD (68% v 52% at 3 years; OR = 1.92; 95% CI, 1.47 to 2.49; P < .000001), but not grade 2-4 acute GVHD (54% v 53%; P = .49). PBSCT was associated with a decrease in relapse (21% v 27% at 3 years; OR = 0.71; 95% CI, 0.54 to 0.93; P = .01) in both late-stage–(33% v 51% at 3 years; OR = 0.59; 95% CI, 0.38 to 0.93; P = .02) and early-stage–disease patients (16% v 20% at 3 years; OR = 0.69; 95% CI, 0.49 to 0.98; P = .04). Nonrelapse mortality was not different between groups. Overall and disease-free survival were only statistically significantly improved in patients with late-stage disease (overall survival: 46% v 31% at 3 years; OR = 0.64; 95% CI, 0.46 to 0.90; P = .01; disease-free survival: 41% v 27% at 3 years; OR = 0.63 95% CI, 0.45 to 0.87; P = .01). Conclusion: PBSCT is associated with a decreased relapse rate in hematologic malignancies and improvement in overall and disease-free survival in patients with late-stage disease. PBSCT is also associated with a significant risk of extensive chronic GVHD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
Moher, D., Cook, D. J., Eastwood, S., Olkin, I., Rennie, D., & Stroup, D. F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04149-5 · Cited by 4,826
Gooley, T. A., Leisenring, W., Crowley, J., & Storer, B. E. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o · Cited by 2,688
Focan, C., Steinberg, S. M., Blichert-Toft, M., Forbes, J., Collins, R. D., Anderson, S., Margreiter, R., Harwood, C. S., Andersen, K., Beighton, G., et al. (1998) · PubMed · Cited by 2,146
Polychemotherapy for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(98)03301-7 · Cited by 2,042
Bensinger, W. I., Martin, P. J., Storer, B., Clift, R., Forman, S. J., Negrin, R., Kashyap, A., Flowers, M. E. D., Lilleby, K., Chauncey, T. R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200101183440303 · Cited by 962
Practical methodology of meta‐analyses (overviews) using updated individual patient data
Stewart, L. A., & Cochrane Working Group On Meta‐Analysis Using Individual Patient Data (1995) · Statistics in Medicine · doi:10.1002/sim.4780141902 · Cited by 492
Körbling, M., & Anderlini, P. (2001) · Blood · doi:10.1182/blood.v98.10.2900 · Cited by 361
Powles, R., Mehta, J., Kulkarni, S., Treleaven, J., Millar, B., Marsden, J., Shepherd, V., Rowland, A., Sirohi, B., Tait, D., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02090-0 · Cited by 354
Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials
Collins, R., & MacMahon, S. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03651-5 · Cited by 337
Cited by
Risk factors for acute GVHD and survival after hematopoietic cell transplantation
Jagasia, M., Arora, M., Flowers, M. E. D., Chao, N. J., McCarthy, P. L., Cutler, C. S., Urbano-Ispizua, A., Pavletic, S. Z., Haagenson, M. D., Zhang, M.-J., et al. (2012) · Blood · doi:10.1182/blood-2011-06-364265 · Cited by 707
Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease
Kröger, N., Solano, C., Wolschke, C., Bandini, G., Patriarca, F., Pini, M., Nagler, A., Selleri, C., Risitano, A., Messina, G., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506002 · Cited by 573
Bashey, A., Zhang, X., Sizemore, C. A., Manion, K., Brown, S., Holland, H. K., Morris, L. E., & Solomon, S. R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.3523 · Cited by 499
Solid cancers after allogeneic hematopoietic cell transplantation
Rizzo, J. D., Curtis, R. E., Socié, G., Sobocinski, K. A., Gilbert, E., Landgren, O., Travis, L. B., Travis, W. D., Flowers, M. E. D., Friedman, D. L., et al. (2009) · Blood · doi:10.1182/blood-2008-05-158782 · Cited by 439
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation
Landgren, O., Gilbert, E. S., Rizzo, J. D., Socié, G., Banks, P. M., Sobocinski, K. A., Horowitz, M. M., Jaffe, E. S., Kingma, D. W., Travis, L. B., et al. (2009) · Blood · doi:10.1182/blood-2008-09-178046 · Cited by 400
Metadata
- Venue
- Journal of Clinical Oncology
- Published
- 2005-08-01
- Volume
- 23
- Issue
- 22
- Pages
- 5074-5087
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2155722011
- Cited by
- 451
- References
- 19
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Allogeneic Peripheral Blood Stem-Cell Compared With Bone Marrow Transplantation in the Management of Hematologic Malignancies: An Individual Patient Data Meta-Analysis of Nine Randomized Trials. https://app.cochat.ai/papers/10.1200/jco.2005.09.020
- The paper
- Allogeneic Peripheral Blood Stem-Cell Compared With Bone Marrow Transplantation in the Management of Hematologic Malignancies: An Individual Patient Data Meta-Analysis of Nine Randomized Trials. (2005). Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.09.020
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
